{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T10:29:09Z","timestamp":1786530549143,"version":"build-2736575974"},"reference-count":18,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe Cushing syndrome (CS) is a rare diagnosis with high mortality, which limits the ability of endocrinologists to gain experience delivering care. Here we describe our experience treating 3 cases of ectopic ACTH-dependent CS presenting in a single year. The initial diagnosis of each case was made during hospitalization resulting from complications of CS, implicating severe disease and delayed diagnosis. Our experience suggests that rapid initiation and titration of osilodrostat effectively treats hypercortisolism and improves outcomes.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag213","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:39:41Z","timestamp":1784288381000},"source":"Crossref","is-referenced-by-count":0,"title":["Ectopic ACTH-dependent Cushing syndrome in 3 hospitalized patients: lessons learned from management with osilodrostat"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5020-8262","authenticated-orcid":false,"given":"Hannah","family":"Ruggles","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-9971","authenticated-orcid":false,"given":"Emmy","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Geriatric Medicine, Department of Internal Medicine, The University of North Carolina at Chapel Hill , Chapel Hill, NC 27514, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-8150","authenticated-orcid":false,"given":"Nikita","family":"Mohan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7245-1639","authenticated-orcid":false,"given":"Luis Borges","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9836-4426","authenticated-orcid":false,"given":"Elizabeth","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-7309","authenticated-orcid":false,"given":"Morgan","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"5","key":"2026081205121363400_luag213-B1","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1210\/clinem\/dgab058","article-title":"Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality","volume":"106","author":"Schernthaner-Reiter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026081205121363400_luag213-B2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/EJE-19-0464","article-title":"High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026081205121363400_luag213-B3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026081205121363400_luag213-B4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","article-title":"A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease","volume":"67","author":"Tanaka","year":"2020","journal-title":"Endocr J"},{"issue":"7","key":"2026081205121363400_luag213-B5","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081205121363400_luag213-B6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing's syndrome: results from a single center cohort study","volume":"13","author":"Detomas","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2026081205121363400_luag213-B7","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1007\/s12325-025-03229-0","article-title":"Matching-adjusted indirect comparison of osilodrostat versus metyrapone for the treatment of Cushing's syndrome","volume":"42","author":"Hickey","year":"2025","journal-title":"Adv Ther"},{"issue":"6","key":"2026081205121363400_luag213-B8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081205121363400_luag213-B9","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz136","article-title":"Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients","volume":"105","author":"Rubinstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081205121363400_luag213-B10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026081205121363400_luag213-B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101521","article-title":"Epidemiology and mortality of Cushing's syndrome","volume":"35","author":"Hakami","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026081205121363400_luag213-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-11-0601","article-title":"Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome","volume":"166","author":"Yiu","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026081205121363400_luag213-B13","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/clinem\/dgae258","article-title":"Personalized noninvasive diagnostic algorithms based on urinary free cortisol in ACTH-dependant Cushing's syndrome","volume":"109","author":"Lavoillotte","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081205121363400_luag213-B14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for Cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026081205121363400_luag213-B15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","article-title":"Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026081205121363400_luag213-B16","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf039","article-title":"Etomidate in severe Cushing syndrome: a systematic review","volume":"9","author":"Muthukuda","year":"2025","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026081205121363400_luag213-B17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s12020-024-04135-1","article-title":"Is there still a place for etomidate in the management of Cushing's syndrome? The experience of a single center of low-dose etomidate and combined etomidate-osilodrostat treatment in severe hypercortisolemia","volume":"87","author":"Dzialach","year":"2025","journal-title":"Endocrine"},{"issue":"4","key":"2026081205121363400_luag213-B18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40618-025-02769-0","article-title":"Efficacy and safety of osilodrostat in patients with ectopic Cushing\u00b4s syndrome. a real-world study in Spain","volume":"49","author":"Araujo-Castro","year":"2026","journal-title":"J Endocrinol Invest"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag213\/70616488\/luag213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag213\/70616488\/luag213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:35:21Z","timestamp":1786527321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag213\/8759421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag213","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,27]]},"article-number":"luag213"}}